LPA anticorps

N° du produit ABIN113082

Détail du produit anti-LPA anticorps

Antigène: LPA (APOA) (Apolipoprotein A (APOA))

Reactivité: Mammifères

Hôte: Mouton

Clonalité: Polyclonal

Conjugué: Cet anticorp LPA est non-conjugé

Application: Western Blotting (WB), Enzyme Immunoassay (EIA)

Specificité: Specifically binds to human Lp(a) and apo(a). No cross-reaction to Apo B-100/48, minor to plasminogen.

Purification: Human Apo (a) Sepharose affinity column. Cross-reactivity to plasminogen was removed by passing plasminogen Sepharose affinity column.

Information d'application

Indications d'application: Suitable for use in ELISA (1: 7,500-1: 60,000), Western blot and conjugation purposes.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Concentration: 1,0 mg/mL (OD280nm, E0.1% = 1.35)

Buffer: 75 mM PBS, 75 m mM Sodium chloride, pH 7.2 containing 0.02 % Sodium azide as preservative.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Détails sur LPA

Antigène: LPA (APOA) (Apolipoprotein A (APOA))

Autre désignation: Apolipoprotein(a) / LP(a) (APOA Produits)

Synonymes: anticorps AK38, anticorps APOA, anticorps LP, anticorps Apo(a), anticorps Lp(a), anticorps lipoprotein(a), anticorps LPA

Sujet: Lipoprotein(a) (Lp(a)) is a lipoprotein subclass assembled in the blood from low density lipoprotein (LDL) molecules and apolipoprotein-a (apo-a). Lp(a) recruits inflammatory cells through interaction with Mac-1 integrin. High Lp(a) in blood is a risk factor for coronary heart disease, cerebrovascular disease, atherosclerosis, thrombosis, and stroke. Lp(a) concentrations may be affected by disease states, but are only moderately affected by diet, exercise and other environmental factors. Lipid-reducing drugs have no effect on Lp(a) concentration. High Lp(a) predicts risk of early atherosclerosis similar to high LDL, but in advanced atherosclerosis, Lp(a) is a risk factor independent of LDL, indicating a coagulant risk of plaque thrombosis. Apo(a) contains domains that are very similar to plasminogen (PLG). Lp(a) accumulates in the vessel wall and inhibits binding of PLG to the cell surface, reducing plasmin generation which increases clotting. This inhibition also promotes proliferation of smooth muscle cells. These unique features of Lp(a) suggest a role in the generation of clots and atherosclerosis.Synonyms: Apo(a), LPA

ID gène: 4018

NCBI Accession: NP_005568

UniProt: P08519